For prostate cancer, statins may disrupt lipid rafts, which impairs key signalling pathways including the androgen receptor (AR), EGFR, and PI3K–AKT, thereby reducing tumour growth.36 The gene discussed is AKT1; the disease is prostate carcinoma.